Box-office blockbusters, muted stock returns: Is Dalal Street buying the cinema boom?

From Dhurandhar 2 and Ramayana to Drishyam 3 have generated substantial collections, but the relationship between box-office performance and listed entertainment stocks remains complicated

by e4m Staff
Published: Nov 14, 2026 8:42 AM | 2 min read

In 2026, India's box office is experiencing significant success, with films like "Dhurandhar: The Revenge" grossing Rs 1,852.44 crore and "Ramayana: Part I" surpassing Rs 1,000 crore in worldwide collections.
Despite the box office triumphs, the stock market response has been inconsistent, as seen with Prime Focus Ltd's shares declining by approximately 10.3% following the release of "Ramayana."
"Drishyam: The Conclusion" also performed well at the box office, collecting around Rs 576.57 crore, but its producer, Panorama Studios International, faces similar challenges in translating box office success into stock performance.
The exhibition sector, represented by PVR INOX, reported a profit increase for the September quarter, yet this reflects broader operations rather than the impact of individual films, raising questions about the sustainability of shareholder value in the film industry.

India's box office is delivering some extraordinary numbers in 2026. Films are crossing hundreds of crores, advance bookings are generating excitement and cinema advertising inventory is attracting renewed interest. Yet, while theatres celebrate blockbuster collections, the response on Dalal Street has been considerably less predictable.

Consider Dhurandhar: The Revenge, which leads the 2026 Hindi box-office charts with worldwide collections of Rs 1,852.44 crore, according to Bollywood Hungama, an entertainment news and trade platform that tracks film releases, box-office collections and industry developments. Produced by Jio Studios and B62 Studios, the film illustrates the scale of theatrical success. However, Jio Studios is part of Reliance Industries' much larger business ecosystem, making the film's contribution difficult to isolate in the parent company's stock performance.

Then there is Ramayana: Part I, which crossed Rs 1,000 crore worldwide, according to Bollywood Hungama's November 13 box-office rankings. The film's production company, Prime Focus Studios, is associated with listed Prime Focus Ltd, whose shares have followed a different trajectory.

According to historical trading data from the BSE, Prime Focus shares closed at Rs 306.05 on November 4, ahead of Ramayana's release, before declining to Rs 274.60 on November 12, a fall of approximately 10.3%. The decline highlights the contrast between the film's box-office momentum and investor sentiment.

Drishyam: The Conclusion offers another example. The Ajay Devgn-starrer collected approximately Rs 576.57 crore worldwide, according to Bollywood Hungama. Its producer, Panorama Studios International, is listed on the BSE, giving investors exposure to a company directly involved in film production.

The exhibition business presents a different picture. PVR INOX reported consolidated profit after tax from continuing operations of Rs 263.1 crore for the September quarter, compared with Rs 108.2 crore a year earlier, according to its October 28 exchange filing. However, these results preceded Ramayana's theatrical release and reflect the company's wider operations rather than any single film.

The distinction matters because successful theatrical releases create commercial opportunities beyond ticket sales. Higher footfalls can support food and beverage spending, cinema advertising, sponsorships and other revenue streams.

For investors, however, the calculations extend to production costs, revenue-sharing arrangements, profitability, debt and future release pipelines. Even films generating substantial box-office collections do not necessarily translate into equivalent earnings for their associated listed companies.

As Ramayana keeps the spotlight on theatrical entertainment, the larger question remains: can India's blockbuster economy create sustained shareholder value, or will box-office records and stock-market returns continue to tell different stories?